Iterum Therapeutics plc — Director's Dealing 2018

May 30, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2018-05-30

Reporting Person: Dunne Michael W. (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-05-30	Ordinary Shares	C	12730	—	Acquired	137491	Direct
2018-05-30	Ordinary Shares	C	4050	—	Acquired	141541	Direct
2018-05-30	Ordinary Shares	C	2917	—	Acquired	144458	Direct
2018-05-30	Ordinary Shares	P	2000	$13.00	Acquired	146458	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-30	Series A Preferred Shares	$	C	12730	Disposed		Ordinary Shares (12730)	Direct
2018-05-30	Series B-1 Preferred Shares	$	C	4050	Disposed		Ordinary Shares (4050)	Direct
2018-05-30	Series B-2 Preferred Shares	$	C	2917	Disposed		Ordinary Shares (2917)	Direct

Footnotes

F1: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F2: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F3: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F4: Not applicable.